ATM Mutations and E-cadherin Expression Define Sensitivity to EGFR-targeted Therapy in Colorectal Cancer
Overview
Authors
Affiliations
EGFR-targeted therapy is a key treatment approach in patients with RAS wildtype metastatic colorectal cancers (CRC). Still, also RAS wildtype CRC may be resistant to EGFR-targeted therapy, with few predictive markers available for improved stratification of patients. Here, we investigated response of 7 CRC cell lines (Caco-2, DLD1, HCT116, HT29, LS174T, RKO, SW480) to Cetuximab and correlated this to NGS-based mutation profiles, EGFR promoter methylation and EGFR expression status as well as to E-cadherin expression. Moreover, tissue specimens of primary and/or recurrent tumors as well as liver and/or lung metastases of 25 CRC patients having received Cetuximab and/or Panitumumab were examined for the same molecular markers. In vitro and in situ analyses showed that EGFR promoter methylation and EGFR expression as well as the MSI and or CIMP-type status did not guide treatment responses. In fact, EGFR-targeted treatment responses were also observed in RAS exon 2 p.G13 mutated CRC cell lines or CRC cases and were further linked to PIK3CA exon 9 mutations. In contrast, non-response to EGFR-targeted treatment was associated with ATM mutations and low E-cadherin expression. Moreover, down-regulation of E-cadherin by siRNA in otherwise Cetuximab responding E-cadherin positive cells abrogated their response. Hence, we here identify ATM and E-cadherin expression as potential novel supportive predictive markers for EGFR-targeted therapy.
Chantre-Justino M, Silvestre R, De Castro T, Luz E, Pinheiro R, Caruso A Biomed Rep. 2025; 22(3):42.
PMID: 39810900 PMC: 11729137. DOI: 10.3892/br.2025.1920.
Role of Cell-Cell Junctions in Oesophageal Squamous Cell Carcinoma.
Xu Q, Du X, Huang T, Zheng Y, Li Y, Huang D Biomolecules. 2022; 12(10).
PMID: 36291586 PMC: 9599896. DOI: 10.3390/biom12101378.
Bruun J, Eide P, Bergsland C, Bruck O, Svindland A, Arjama M Mol Oncol. 2021; 16(12):2312-2329.
PMID: 34890102 PMC: 9208074. DOI: 10.1002/1878-0261.13159.
Tumor Inhibitory Effect of Long Non-coding RNA LOC100505817 on Gastric Cancer.
Zheng L, Kang L, Cheng Y, Cao J, Liu L, Xu H Pathol Oncol Res. 2021; 27:581542.
PMID: 34385891 PMC: 8354317. DOI: 10.3389/pore.2021.581542.
Zhuang Y, Wang H, Jiang D, Li Y, Feng L, Tian C BMC Cancer. 2021; 21(1):380.
PMID: 33836681 PMC: 8034139. DOI: 10.1186/s12885-021-08108-9.